Genedata Establishes New Standard for Biopharma Quality Control with NGS, Ensuring Genetic Stability in CGT

Genedata Switzerland

Overview

Genedata highlights Next-Generation Sequencing (NGS) as a powerful analytical tool for biopharmaceutical quality control (QC). NGS offers GxP-compliant workflows and supports data integrity and streamlined compliance, recognized by major regulatory bodies like FDA and EMA. Crucially for Cell and Gene Therapies (CGT), NGS continuously monitors genetic stability and viral vector genome integrity, evaluating mutations, truncations, recombinations, integration events, and plasmid instability, essential for guaranteeing final product safety and efficacy.

In Depth

Key Finding: NGS Establishes a New Standard for Biopharma Quality Control, Ensuring Genetic Stability in CGT

Genedata emphasized that Next-Generation Sequencing (NGS) technology has emerged as a powerful analytical tool, fundamentally transforming the paradigm of quality control (QC) in the biopharmaceutical industry. With its comprehensiveness and high sensitivity, NGS possesses the capability to identify genetic changes that were difficult to detect with traditional QC methods. This technology is integrated into GxP (Good x Practice)-compliant workflows and is recognized by major regulatory authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) as a tool that supports data integrity and streamlined compliance. This elevates the assurance of safety and efficacy for biopharmaceuticals, particularly Cell and Gene Therapy (CGT) products, to a new level.

Technical & Clinical Details: NGS Applications and Quality Assessment Parameters

• Comprehensive Genetic Stability Monitoring: NGS provides high-resolution sequencing data across the entire genome of cell lines and viral vectors. This enables continuous monitoring of the following critical quality attributes:
  1. Mutation Detection: Detects unexpected genetic mutations such as point mutations, insertions, and deletions with high sensitivity.
  2. Truncation and Recombination Events: Identifies potential viral vector truncations or recombination events that may occur during the manufacturing process, assessing the risk of vector functional loss.
  3. Integration Site Analysis: Accurately maps the integration sites of gene therapy vectors into the host genome, evaluating potential safety risks (e.g., oncogenicity).
  4. Plasmid Instability: Monitors the stability of plasmid DNA used in manufacturing, ensuring the supply of high-quality raw materials.
• GxP-Compliant Workflows: Genedata provides solutions for integrating NGS-based QC workflows into GxP environments. This includes sample tracking, data management, validation of analytical pipelines, and audit trail functionalities, supporting robust compliance with regulatory requirements.
• Data Integrity and Compliance: The vast amount of data generated by NGS must be managed in accordance with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available). NGS-based QC simplifies data integrity maintenance and regulatory reporting through automated data collection, analysis, and report generation.

Background & Industry Context: Specificity of CGT and QC Challenges

Cell and gene therapy products present unique QC challenges distinct from traditional small molecule drugs or biopharmaceuticals, owing to their complex biological nature and irreversible effects. Specifically, the genetic stability of cell lines and the genomic integrity of viral vectors are directly linked to product safety and efficacy, thus requiring stringent monitoring. Traditional methods like PCR or electrophoresis have found it difficult to comprehensively detect these complex changes.

Future Outlook: Driving Personalized Medicine and Real-Time Release

The implementation of NGS for QC is an indispensable factor for enhancing the reliability of CGT products and accelerating the widespread adoption of personalized medicine. This technology promotes a deep understanding of manufacturing processes and strengthens Quality by Design (QbD) principles. In the future, NGS-based QC will serve as a crucial foundation for enabling ‘real-time release’ strategies (an approach that significantly simplifies and speeds up final product quality testing) for biopharmaceuticals, delivering safer and more effective therapies to patients faster. Continuous technological development and collaboration with regulatory authorities will drive further evolution in this field.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime